SCHEMBL6663983

SCHEMBL6663983

N#CC(CO)c1ccc2ccccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
HSD17B10 Q99714 1/20 0.43
KDM4E B2RXH2 3/20 0.40
GAA P10253 2/20 0.40
CYP1A2 P05177 3/20 0.36
MAPT P10636 3/20 0.36
GLA P06280 1/20 0.36
HPGD P15428 1/20 0.36
ACHE P22303 1/20 0.36
NCF1 P14598 2/20 0.36
NOS2 P35228 1/20 0.36
BACE1 P56817 1/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
MGAM O43451 1/20 0.36
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34
HTT P42858 2/20 0.34
AR P10275 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267344 0.78 NCF1 (0.43) ALDH1A1HSD17B10KDM4EGAACYP1A2
SCHEMBL26512422 0.77 NCF1 (0.42) ALDH1A1HSD17B10KDM4EGAACYP1A2
SCHEMBL31376529 0.75 ALDH1A1 (0.59) ALDH1A1HSD17B10KDM4EGAACYP1A2
SCHEMBL1848409 0.75 ALDH1A1 (0.59) ALDH1A1HSD17B10KDM4EGAACYP1A2
SCHEMBL28320052 0.74 ALDH1A1 (0.46) ALDH1A1HSD17B10KDM4EGAACYP1A2
SCHEMBL11251120 0.74 NCF1 (0.40) ALDH1A1HSD17B10KDM4EGAACYP1A2
SCHEMBL18704072 0.73 ALDH1A1 (0.54) ALDH1A1HSD17B10KDM4EGAACYP1A2
SCHEMBL7995244 0.72 ALDH1A1 (0.51) ALDH1A1HSD17B10KDM4EGAACYP1A2
SCHEMBL29157816 0.71 CYP1A2 (0.41) ALDH1A1HSD17B10KDM4EGAACYP1A2
SCHEMBL10020390 0.70 ALDH1A1 (0.53) ALDH1A1HSD17B10KDM4EGAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1251123-B1 PROCESS FOR PREPARING QUINOLYLACRYLONITRILE AND INTERMEDIATES THEREFOR NISSAN CHEMICAL IND LTD (JP) 2004-07-21 EP disclosed
US-6541636-B2 Such as 3-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl) prop-2-enenitrile by reacting 2-cyclopropyl-4-(4-fluorophenyl) quinoline-3-carbaldehyde with acetonitrile in the presence of base, then dehydrating; enzyme inhibitors UBE INDUSTRIES, LTD. (JP) 2003-04-01 US disclosed
US-20030013885-A1 PROCESS FOR PREPARING QUINOLYLACRYLONITRILE AND INTERMEDIATES THEREFOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-16 US disclosed
EP-1251123-A1 PROCESS FOR PREPARING QUINOLYLACRYLONITRILE AND INTERMEDIATES THEREFOR Ube Industries, Ltd. (JP) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013885-A1 PROCESS FOR PREPARING QUINOLYLACRYLONITRILE AND INTERMEDIATES THEREFOR WEE2, WEE1, CYP4F11 ALDH1A1 643/4885HSD17B10 1271/4885KDM4E 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.